Improving the Lives of People Living with Neurodegenerative Diseases
Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer’s disease (AD).
Every Neuraltus employee is working to advance therapies that have the potential to make a difference in the lives of people living with these often devastating neurological conditions. We combine world-class scientific expertise, a robust patent portfolio and a strong commitment to working with the patient community to develop innovative treatments. Neuraltus is configured as a “virtual” drug development organization. We have a small internal team and a network of experienced advisors and service providers to advance our development programs.
Neuraltus began operations in 2004 based on a broad technology portfolio and intellectual property assembled by the company founders. Neuraltus has received more than $55 million in financing from leading venture groups, including VantagePoint Capital Partners and Latterell Venture Partners, to support its research and drug development efforts.
Our lead product, NP001, is in clinical development for the treatment of ALS, also known as Lou Gehrig’s disease.
ALS is a fatal neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. The cause of the disease is currently unknown, but there is increasing evidence that associates neuroinflammation with the progression of the disease. It is believed that in people with ALS, there are increased levels of inflammatory or activated macrophages. Macrophages are a type of white blood cell that, in response to certain triggers, become activated and can be found in tissues of the body. When in an activated state, they release a number of compounds that result in inflammation and lead to motor neuron damage and death. NP001, a regulator of macrophage activation, converts these activated inflammatory macrophages back to their normal, non-inflammatory state.